CN114426941A - Lactobacillus paracasei Glu-07 and application thereof - Google Patents
Lactobacillus paracasei Glu-07 and application thereof Download PDFInfo
- Publication number
- CN114426941A CN114426941A CN202210340233.0A CN202210340233A CN114426941A CN 114426941 A CN114426941 A CN 114426941A CN 202210340233 A CN202210340233 A CN 202210340233A CN 114426941 A CN114426941 A CN 114426941A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- glu
- lactobacillus
- paracasei
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of microorganisms and application thereof, and provides lactobacillus paracasei (Lactobacillus paracasei)Lactobacillus paracasei) Glu-07 with the preservation number of CGMCC No. 23796. The invention also provides lactobacillus paracaseiLactobacillus paracasei) Glu-07 is used for preventing and treating postprandial hyperglycemia and/or relieving hyperinsulinemia and preventing and treating hyperlipidemia. The lactobacillus paracasei Glu-07 provided by the invention has good effects of preventing and treating postprandial hyperglycemia, relieving hyperinsulinemia and improving hyperlipidemia, and provides a very good product for effectively preventing and treating postprandial hyperglycemia and hyperlipidemia in the futureGood scientific basis and great potential market value.
Description
Technical Field
The invention belongs to the field of microorganisms and application thereof, and particularly relates to lactobacillus paracasei Glu-07 and application thereof.
Background
Obesity is a chronic, complex and multifactorial disease, the fifth most risk factor for global death, causing nearly 340 million deaths each year. Epidemiological studies have shown that there are currently 21 billion more people worldwide who are overweight or obese, and if continued according to the current trend, it is expected that by 2030, 38% of the adults worldwide will be overweight, and the other 20% will develop obesity. Obesity is associated with a number of serious complications, and like obesity, the incidence of diabetes has also risen dramatically around the world and is becoming a leading cause of death in many countries. The 8 th version of the diabetes map published by the international diabetes consortium in 2017 highlights some alarming statistics, and it is estimated that about 4.25 million people worldwide will have diabetes, and by 2045, the worldwide number of diabetic patients will reach 6.29 million. In 2017, about 500 million people die of diabetes globally, which means 1 person dies of diabetes every 8 s. According to the American diabetes Association's diagnostic criteria, the prevalence of diabetes among adults in China is 12.8%, the total number of patients is about 1.298 hundred million, that is, 1 diabetic out of about 10 adults on average, and the current population of Chinese diabetic patients is the first to live globally. What is more striking is that the pre-diabetes morbidity of the population in China is 35.2 percent, which is a huge population.
At present, the continuous high blood sugar level of diabetes can cause the vascular injury of organs of the whole body such as heart, kidney, nerve and the like, cause various complications, seriously affect the physical health and the life quality of patients, and are a great public health problem which brings heavy economic burden to the society, so the prevention and treatment work is urgent.
Intestinal flora is another key endogenous factor regulating host metabolism, and our body inhabits as many as 100 trillion commensal microorganisms, which encode approximately 150 times as many genes as human self. Human commensal microorganisms are critical to the health of the host and have been recognized as a truly functional "organ". Numerous studies have shown that the intestinal flora plays an important role in the metabolism and disease state of the host. The gut microbiota can directly or indirectly affect human health, and dysbiosis can increase the prevalence of proinflammatory diseases such as obesity, inflammatory bowel disease, type 2 diabetes, arthritis, and cancer. Currently, development of safe and effective diabetes treatment strategies by taking intestinal microorganisms as targets becomes a research hotspot in the field.
Probiotics are microorganisms beneficial to human bodies, and compared with traditional hypoglycemic drugs, the probiotics have high safety and do not generate additional side effects on organisms, so that the development and efficacy research of the probiotics in China is actively carried out in recent years. The lactobacillus contains abundant strains with the capability of reducing blood sugar, and is mainly derived from probiotic strains such as lactobacillus plantarum, lactobacillus gasseri, lactobacillus reuteri, lactobacillus fermentum, lactobacillus casei, lactobacillus paracasei and the like. The strain contained in the 'Yangladuo' lactobacillus beverage of great famous tripod is a lactobacillus casei field strain, and the indigenous lactobacillus casei Zhang in China is also reported to have excellent functions of improving body immunity, resisting tumors, improving lipid metabolism and the like. At present, 35 edible probiotic strains or subspecies have been published in China, but because the functions of the probiotics have strain specificity, deep functional mining on the strain level of the probiotic resources in China can provide scientific basis for accurately developing strain products for treating abnormal glycolipid metabolism.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides lactobacillus paracasei Glu-07 with the efficacy of reducing hyperglycemia and hyperlipidemia and application thereof; the lactobacillus paracasei Glu-07 can obviously inhibit the activity of alpha-glucosidase, can obviously reduce the fasting blood glucose value of a diabetic mouse and inhibit the increase of the postprandial blood glucose value of the diabetic mouse, and the Glu-07 strain has excellent improving effect on a mouse fed with high fat.
In a first aspect, the present invention provides Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 with the preservation number of CGMCC No. 23796.
In a second aspect, the invention provides the use of a formulation comprising at least one of the following for the prevention and treatment of post-prandial hyperglycemia and/or for the relief of hyperinsulinemia:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC No. 23796) with preservation number of CGMCC No. in the first aspect of the inventionLactobacillus paracasei）Glu-07。
In a third aspect, the invention provides the use of a formulation comprising at least one of the following in the manufacture of a product for the prevention and treatment of postprandial hyperglycemia and/or the relief of hyperinsulinemia:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC No. 23796) with preservation number of CGMCC No. in the first aspect of the inventionLactobacillus paracasei）Glu-07。
In a fourth aspect, the invention provides a product for preventing and treating postprandial hyperglycemia and/or relieving hyperinsulinemia, which comprises at least one of the following components:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei (L.), (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei with preservation number of CGMCC number 23796 (see the first aspect of the invention)Lactobacillus paracasei）Glu-07。
In a fifth aspect, the present invention provides use of a formulation comprising at least one of:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (L.), (Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC No. 23796) with preservation number of CGMCC No. in the first aspect of the inventionLactobacillus paracasei）Glu-07。
The invention provides the application of a preparation containing at least one of the following in preparing a product for preventing and treating hyperlipidemia:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC No. 23796) with preservation number of CGMCC No. in the first aspect of the inventionLactobacillus paracasei）Glu-07。
The seventh aspect of the present invention provides a product for preventing and treating hyperlipidemia, which contains at least one of:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC No. 23796) with preservation number of CGMCC No. in the first aspect of the inventionLactobacillus paracasei）Glu-07。
Preservation description:
the strain name is as follows: glu-07
Latin name:Lactobacillus paracasei
and (3) classification and naming: lactobacillus paracasei
The strain number is as follows: CGMCC No.23796
The preservation organization: china general microbiological culture Collection center
The preservation organization is abbreviated as: CGMCC
Address: xilu No. 1 Hospital No. 3 of Beijing market facing Yang district
The preservation date is as follows: 11/12/2021
Registration number of the preservation center: CGMCC number 23796
The invention provides lactobacillus paracasei (L.paracasei) ((L.paracasei))Lactobacillus paracasei) Glu-07 has good effects of preventing and treating postprandial hyperglycemia, relieving hyperinsulinemia and improving hyperlipidemia, provides good scientific basis for developing effective products for preventing and treating postprandial hyperglycemia and hyperlipidemia in the future, and has great potential market value.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 shows the results of the evaluation of the inhibition of alpha-glucosidase activity by Lactobacillus paracasei Glu-07 strain in the present invention.
FIG. 2 shows the results of an experiment in which Lactobacillus paracasei Glu-07 of the present invention ameliorates lipid metabolism abnormality in high-fat-fed mice. Wherein (A) shows the weight curve of the high-fat mice after the gavage Glu-07 strain, (B) shows the weight gain of the high-fat mice after the gavage Glu-07 strain, (C) shows the serum TG level of the high-fat mice after the gavage Glu-07 strain, and (D) shows the serum TC level of the high-fat mice after the gavage Glu-07 strain. n =10, < 0.05, < 0.01.
FIG. 3 shows the results of an experiment in which Lactobacillus paracasei Glu-07 of the present invention ameliorates blood glucose abnormality in diabetic mice. Wherein (A) shows the fasting blood glucose value of the diabetic mouse after gastric lavage of Glu-07 strain, and (B) shows the blood glucose value of the diabetic mouse after 1h and 2h of feeding water-soluble starch after gastric lavage of Glu-07 strain, and metformin is used as a positive control. n =10, # p < 0.05, # p < 0.01.
Detailed Description
In order to make the technical solution, objects and advantages of the present invention clearer, the present invention is further described in detail by the following specific embodiments. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are given by way of illustration and explanation only, not limitation.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict between the prior art and the present disclosure, the present disclosure should control.
Various reagents, materials and the like used in the following examples are commercially available products unless otherwise specified; unless otherwise specified, all the tests and detection methods used in the following examples are conventional in the art and can be obtained from textbooks, tool books or academic journals.
Example 1: separation and sequencing identification of Lactobacillus paracasei Glu-07 strain
The lactobacillus paracasei Glu-07 strain is separated from a fecal sample of a rural centenarian aged having long life in Chengmei world in Hainan, and a collected object does not take antibiotic medicines before collection and has no probiotic taking history. Carrying out streak culture on Glu-07 strain frozen at-80 ℃ in an MRS solid culture medium (10 g of peptone, 10 g of beef extract, 5 g of yeast extract, 2 g of diammonium hydrogen citrate, 20 g of glucose, 801 mL of Tween, 5 g of sodium acetate, 2 g of dipotassium hydrogen phosphate, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate, 18 g of agar and 1000 mL of distilled water), carrying out anaerobic culture at 37 ℃ for 24-48h, selecting a single colony to culture in a liquid MRS culture medium, and carrying out anaerobic culture at 37 ℃ for 48h to obtain an activated Glu-07 bacterial liquid. Then, the Glu-07 thalli is used for extracting DNA according to the kit operation instruction, and subsequently, shotgun sequencing is carried out to identify the strain type.
Quality control, splicing and comparative analysis are carried out on a sequence obtained by sequencing, a Glu-07 gene sequence is found to contain two marker genes which are specific to lactobacillus paracasei, the result is shown as a sequence 1 and a sequence 2 in a sequence table, and accordingly, the Glu-07 bacterium is named as lactobacillus paracaseiLactobacillus paracaseiGlu-07 strain.
Example 2: preparation of live bacterial suspensions, metabolites and dead bacterial suspensions
2.1 cultivation of the Strain
Coating the frozen bacterium liquid at minus 80 ℃ on an MRS solid plate, carrying out inverted culture at 37 ℃ for 24-48h, inoculating a single colony in a liquid MRS culture medium, and carrying out culture at 37 ℃ for 18-24h to obtain a first-generation bacterium liquid F1; inoculating 10% of first-generation bacterium liquid to a fresh MRS liquid culture medium, and culturing at 37 ℃ for 18-24h to obtain second-generation bacterium liquid F2; inoculating 10% of the second-generation bacterial liquid into a fresh MRS liquid culture medium, and culturing at 37 ℃ for 18-24h to obtain working bacterial liquid.
2.2 obtaining a suspension of viable bacteria
And (3) placing the working bacterial liquid obtained in the step (2.1) at 13000 rpm and 4 ℃ for centrifugation for 15 min, then removing the supernatant, collecting the precipitate, and carrying out resuspension by using normal saline to obtain the viable bacteria suspension with viable bacteria.
Viable bacterial suspensions can also be obtained by other means in the art, as long as the bacteria can be enriched from the culture. This can be achieved, for example, by means of centrifugation and/or filtration.
2.3 obtaining of metabolites
Since the metabolite of the cells is generally present in the culture solution of the cells, the culture solution of the cells can be subjected to solid-liquid separation, and the obtained supernatant is the metabolite. Of course, the preparation of the metabolite can also be carried out under anaerobic conditions. Specifically, working bacteria liquid is centrifuged at 13000 rpm for 10 min at 4 ℃, supernatant is collected and transferred to a sterile centrifuge tube, and then a metabolite for test can be obtained and stored at 4 ℃ for later use.
2.4 obtaining a suspension of dead bacteria
The suspension of dead bacteria may be prepared by means conventional in the art, for example, by heating, irradiation, and the like. For example, the viable bacteria suspension is heated for 1h to kill at 65-85 deg.C to obtain dead bacteria suspension containing dead bacteria.
Example 3: evaluation of alpha-glucosidase inhibitory activity of Lactobacillus paracasei Glu-07 strain
Mixing a 30 mu L sample of Lactobacillus paracasei Glu-07 (including viable bacteria suspension and metabolites) with 30 mu L of alpha-glucosidase enzyme solution (0.1U/mL), incubating at 37 ℃ for 10 min, adding 60 mu L of substrate PNPG (0.5 mM), reacting at 37 ℃ for 20 min, and adding 100 mu L of 2M sodium carbonate solution to terminate the reaction. Then, the absorbance OD at 405nm was measured by a microplate reader405. The MRS medium is used as a negative control, acarbose is used as a positive control, and the experimental results are shown in figure 1.
The results in fig. 1 show that: the inhibition rate of the acarbose in the positive control group is 28.6%, and the inhibition rates of the alpha-glucosidase in the viable bacteria suspension and the metabolite in the experimental group Glu-07 are respectively as high as 27.1% and 27.7%, which indicates that the Glu-07 strain and the metabolite secreted to the extracellular space thereof have strong alpha-glucosidase inhibition activity. Because the substance with alpha-glucosidase inhibitory activity can effectively inhibit the absorption of glucose by the small intestine, the substance can prevent and treat postprandial hyperglycemia and relieve hyperinsulinemia. Therefore, the strain provided by the invention has high possibility of playing the effects of preventing and treating postprandial hyperglycemia and relieving hyperinsulinemia in vivo.
Example 4: lactobacillus paracasei Glu-07 improves hyperlipidemia symptoms in high-fat fed mice
The strain Glu-07 was administered to mice, and the improvement efficacy of the Glu-07 strain on hyperlipidemic mice was observed by the following procedure:
the mice are purchased from Beijing Wittingle, 40 male C57BL/6 mice of 8 weeks old, and are randomly divided into 4 groups, namely a normal group, a high-fat + Glu-07 live bacteria suspension group and a high-fat + Glu-07 dead bacteria suspension group, wherein each group comprises 10 animals. The normal group was given standard mouse diet, and the remaining groups were given high fat diet feeding with 60% fat function, wherein the group of high fat + Glu-07 viable bacteria suspension was administered per one groupDaily administration is 1X 109A Glu-07 viable bacteria suspension corresponding to CFU; the high-fat group and Glu-07 dead bacteria suspension group was administered with a heavy suspension of inactivated bacteria daily, and the high-fat group was administered with an equal volume of physiological saline. Mice were weighed weekly for 4 weeks and body weight data recorded. After 4 weeks, anaesthesia with chloral hydrate, bleeding at the orbit, centrifugation at 4 ℃ and supernatant as serum sample were taken for measurement of serum triglyceride TG and total cholesterol TC content, while animals were sacrificed. Subtracting the weight of the mouse before gastric lavage from the weight of the mouse before dissection to obtain data, namely the weight gain; the final test results are shown in fig. 2.
As can be seen from fig. 2, continuous feeding of high fat diet resulted in significant weight gain (fig. 2, panels a and B), indicating that high fat diet significantly promoted obesity; fig. 2C and D show that the triglyceride TG content and total cholesterol TC levels in the serum of the hyperlipidemic animals were increased, showing a pronounced hyperlipidemic phenotype. After the live bacterium suspension or the dead bacterium suspension of the lactobacillus casei Glu-07 provided by the invention is perfused, the weight of a mouse is increased, and the levels of triglyceride TG and total cholesterol TC in serum are obviously lower than those of a mouse in a high-fat group. These results show that: when the lactobacillus casei Glu-07 provided by the invention is fed to mice, the weight gain caused by high-fat diet can be obviously inhibited, the serum TG and TC levels of the animals are reduced, and the effect of improving the hyperlipidaemia is shown.
Example 5: lactobacillus paracasei GLU-07 relieves symptoms of hyperglycemia of diabetic mice
This example illustrates that Lactobacillus paracasei Glu-07 of the present invention has significant efficacy in ameliorating hyperglycemia in diabetic mice.
The mice are purchased from Beijing Wittiulihua, are male C57BL/6 mice with the age of 8 weeks, are adaptively bred for about one week, are injected with STZ (80 mg/kg) for one time to carry out diabetes model modeling, and monitor the fasting blood glucose value of the mice after 3 days. Screening 40 mice with fasting blood glucose value more than 10mmol/L to prepare for the diabetic mice to carry out subsequent intragastric lavage experiment, randomly dividing the diabetic mice into 4 groups (model group + MRS, model + Glu-07 viable bacteria suspension group, model + Glu-07 dead bacteria suspension group, model + positive medicine group), carrying out intragastric lavage experiment, Glu-07 viable bacteriaThe groups were given 1X 10 each daily9 CFU Lactobacillus paracasei Glu-07 viable bacteria; glu-07 dead bacteria suspension group was given dead bacteria weight suspension daily, positive drug group was given metformin (200 mg/kg), blank control group was given MRS medium. Mice were monitored weekly for 4 weeks of continuous feeding and statistical analysis of blood glucose data at the fourth week at the end of the experiment was performed, the results are shown in fig. 3. An overnight fast was given one day before the experiment, fasting blood glucose values of the mice were measured the next day, then water-soluble starch (4 g/kg) was given to all groups of mice, and then blood glucose values of the mice were recorded with a roche glucometer at 0, 1, and 2h time points, and blood glucose curves were plotted, with the results shown in fig. 3.
As can be seen from FIG. 3A, the average fasting blood glucose of the model mouse is about 13.7 mmol/L, and after the treatment with metformin, the blood glucose level of the mouse is reduced to about 8.8mmol/L, and the high blood glucose level of the mouse is effectively controlled. Mice in the group of live and dead gastric Glu-07 suspensions also exhibited reduced blood glucose levels, with mean fasting blood glucose levels of about 8.1 mmol/L and 8.3 mmol/L, and blood glucose lowering effects approaching those of metformin drugs. The results show that the viable bacteria and the inactivated bacteria of the lactobacillus paracasei Glu-07 can both obviously reduce the high-altitude abdominal blood sugar value of diabetic mice and improve diabetes, and suggest that Glu-07 has a good blood sugar regulation effect and has potential development value.
After the water-soluble starch is filled into the stomach, the blood sugar value is measured to simulate the postprandial blood sugar, and the blood sugar of mice in all experimental groups is rapidly increased after eating the starch for 1 hour, and the blood sugar value falls back after 2 hours but is still higher than that of the mice which do not eat the starch (figure 3B); wherein, the postprandial blood sugar values (1 h and 2h time points) of the Glu-07 live bacteria suspension, the dead bacteria suspension and the metformin mouse are obviously lower than those of the mice of the model group of the gavage medium MRS, and the mice of the model group show the effect of inhibiting the postprandial blood sugar rise; wherein, the effect of the active bacterial suspension and the dead bacterial suspension of the lactobacillus paracasei Glu-07 is slightly better than that of the metformin group, and the effect of the active bacterial suspension Glu-07 is the most excellent in all experimental groups; these results indicate that Lactobacillus paracasei Glu-07 can well inhibit the increase of postprandial blood glucose level of mice, even exceeding the effect of metformin on postprandial blood glucose management.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> Beijing quantitative health science and technology Co., Ltd
<120> lactobacillus paracasei Glu-07 and application thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 597
<212> DNA
<213> Lactobacillus paracasei (Lactobacillus paracasei)
<400> 1
atgtacgagt attttgaagg cattattcag gcggtgaccc cggcttacat cgtcatcgat 60
gtgcatggca tcgggttccg tctgctggta gccaaccctt atcattttga agctggcgag 120
caaaaacgtg tttatgtgca gctgatcatt cgcgacaacg accagacact ttatggattc 180
gaaggtgctg cggataagcg tacctttaac cagctattga cggtcacagg cattggcccg 240
aagtcagcgt tggccatttt ggcgaacgtg tctagcggcg gcttggcgac tgcgattgct 300
caagatgatg tgaagttttt gactaagttt cctgggatcg gtaagaaaac agctgcccag 360
attatccttg atctcaaagg taaaatcaca acagatggac aaccagcggc agcagcgatt 420
gcaccagttg ccagtgacgt tgattcggaa cttgcagatg cgttagcggc actcgtggca 480
ttgggctacc cgcaacgcac cgttgatggt ctcactgaca cactgaaggc attcagtgcc 540
aagacaactg atgcctattt acgcgaaggc ttgcggctat taagcggcaa ggcttag 597
<210> 2
<211> 600
<212> DNA
<213> Lactobacillus paracasei (Lactobacillus paracasei)
<400> 2
atgcaatatc cagaaccgat cagtaaattg atcgacagtt atatgcgcct cccgggtatc 60
ggggcaaaaa ccgcgacacg gctggctttt tacaccattg atatgaataa ggacgatgtg 120
acggcgttcg ctaaaagtct tgtcgcggca aaagaggatc tgcattattg ttccatttgt 180
ggcaacatta ccgatgagga tccgtgtgct atttgtcgcg ataaaagtcg cgaccaaagc 240
acgatattgg tcgttgaaca acctaaagac gtcatgagca ttgatcgggc tcaggattat 300
catggcttgt atcatgtatt acatggcgtt ttatcaccaa tcgaaggccg cggtcctgaa 360
gatctgaata ttgagagttt gttaaaacgg cttaaggcaa ataaggcagt caaagaagtc 420
attatcgcca ctaatgccac gcctgaaggt gaagccaccg cccaatacct ggctcggctg 480
attaaaccag ctggtattaa ggtcactcgc ttagcccatg ggctgtcggt cggcagtgat 540
attgagtatg ctgatgaaat gaccttgatg aaggcggttg aaggaaggac tgagctgtaa 600
Claims (7)
1. Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 with the preservation number of CGMCC number 23796.
2. Use of a formulation comprising at least one of the following for the prevention and treatment of postprandial hyperglycemia and/or for the relief of hyperinsulinemia:
1) lactobacillus paracasei (L.), (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei（Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
3. Use of a formulation comprising at least one of the following in the manufacture of a product for the prevention and treatment of postprandial hyperglycemia and/or the relief of hyperinsulinemia:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
4. A product for preventing and treating postprandial hyperglycemia and/or relieving hyperinsulinemia, which contains at least one of the following:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) auxiliary setLactobacillus casei (A), (B), (C), (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
5. Use of a formulation comprising at least one of the following:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (A), (B), (C)Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
6. Use of a formulation comprising at least one of the following in the preparation of a product for the prevention and treatment of hyperlipidemia:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei: (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (L.), (Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
7. A product for preventing and treating hyperlipidemia comprises at least one of the following:
1) lactobacillus paracasei: (Lactobacillus paracasei）Glu-07；
2) Lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 microbial inoculum;
3) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 viable bacteria suspension;
4) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 dead bacteria suspension;
5) lactobacillus paracasei (L.), (Lactobacillus paracasei) A Glu-07 metabolite;
6) lactobacillus paracasei: (Lactobacillus paracasei) Glu-07 extract;
wherein, the lactobacillus paracasei (L.), (Lactobacillus paracasei) Glu-07 is Lactobacillus paracasei (CGMCC number 23796) with preservation number of CGMCC No. as claimed in claim 1Lactobacillus paracasei）Glu-07。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340233.0A CN114426941A (en) | 2022-04-02 | 2022-04-02 | Lactobacillus paracasei Glu-07 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210340233.0A CN114426941A (en) | 2022-04-02 | 2022-04-02 | Lactobacillus paracasei Glu-07 and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114426941A true CN114426941A (en) | 2022-05-03 |
Family
ID=81314276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210340233.0A Pending CN114426941A (en) | 2022-04-02 | 2022-04-02 | Lactobacillus paracasei Glu-07 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114426941A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116103195A (en) * | 2022-12-13 | 2023-05-12 | 广东南芯医疗科技有限公司 | Lactobacillus paracasei E6 and application thereof in preparation of hypolipidemic drugs |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014046804A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN110604781A (en) * | 2019-09-23 | 2019-12-24 | 石家庄君乐宝乳业有限公司 | Lactobacillus paracasei N1115-containing bacterial powder capable of preventing and relieving diabetes, and preparation method and application thereof |
| CN111560331A (en) * | 2020-05-15 | 2020-08-21 | 诺佰克（武汉）生物科技有限公司 | Lactobacillus paracasei and application thereof |
-
2022
- 2022-04-02 CN CN202210340233.0A patent/CN114426941A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014046804A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN104968780A (en) * | 2012-09-20 | 2015-10-07 | 普洛特拉有限公司 | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| CN110604781A (en) * | 2019-09-23 | 2019-12-24 | 石家庄君乐宝乳业有限公司 | Lactobacillus paracasei N1115-containing bacterial powder capable of preventing and relieving diabetes, and preparation method and application thereof |
| CN111560331A (en) * | 2020-05-15 | 2020-08-21 | 诺佰克（武汉）生物科技有限公司 | Lactobacillus paracasei and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ZHU ZENG 等: "Ameliorative Effects of Probiotic Lactobacillus paracasei NL41 on Insulin Sensitivity, Oxidative Stress, and Beta-Cell Function in a Type 2 Diabetes Mellitus Rat Model", 《MOL NUTR FOOD RES》, vol. 63, no. 22, 12 September 2019 (2019-09-12), pages 1 - 9 * |
| 张宇 等: "副干酪乳杆菌TD062对Ⅱ型糖尿病小鼠的降糖作用", 《中国食品学报》, vol. 20, no. 05, 31 May 2020 (2020-05-31), pages 106 - 112 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116103195A (en) * | 2022-12-13 | 2023-05-12 | 广东南芯医疗科技有限公司 | Lactobacillus paracasei E6 and application thereof in preparation of hypolipidemic drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| JP2001321163A (en) | Microorganism for treatment of obesity or diabetes mellitus, and medicinal composition containing the same | |
| CN110604749A (en) | Bifidobacterium animalis and its use in controlling diabetes or hyperlipidemia, especially weight gain or obesity | |
| CN114507621B (en) | Lactobacillus plantarum and application thereof in reducing uric acid, weight and inflammation | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN114181864B (en) | Lactobacillus rhamnosus HF01 and application thereof | |
| CN116445346B (en) | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof | |
| KR102543494B1 (en) | Novel probiotics and use thereof | |
| CN113549567B (en) | Lactobacillus rhamnosus NSL0401 with defecation promoting function and application thereof | |
| CN108283285A (en) | A kind of health-care physiotherapeutic food of diabetes | |
| CN114432346A (en) | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof | |
| CN113322216A (en) | Lactobacillus paracasei B111H and application thereof in metabolic syndrome | |
| CN115786207A (en) | Lactobacillus salivarius and application thereof in preparation of medicines for treating and/or preventing diabetes | |
| CN114426941A (en) | Lactobacillus paracasei Glu-07 and application thereof | |
| CN113151070B (en) | Lactobacillus fermentum capable of improving relative abundance of Guttiferae in intestinal tract | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN117343875A (en) | Lactobacillus gasseri MY5 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN114774335B (en) | Bifidobacterium longum 070103 with effects of targeting glucokinase and remarkably reducing blood sugar and blood fat and application thereof | |
| CN115181710B (en) | Lactobacillus salivarius B12WU and application thereof | |
| CN113249264B (en) | Bifidobacterium adolescentis and application thereof in metabolic syndrome | |
| CN113832085B (en) | Lactobacillus pentosus BNPV and application thereof | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN113544255A (en) | Coprolalia for preventing and treating obesity and complications thereof | |
| US20240024385A1 (en) | Probiotic strain for reducing serum uric acid, composition and use thereof | |
| CN115806911B (en) | Lactobacillus plantarum, separation method, application, medicine and food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220503 |